These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33920985)

  • 1. Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
    Cacabelos R; Carril JC; Corzo L; Fernández-Novoa L; Pego R; Cacabelos N; Cacabelos P; Alcaraz M; Tellado I; Naidoo V
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33920985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and therapeutic prospects in dementia.
    Cacabelos R
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
    Cacabelos R
    Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics.
    Cacabelos R; Carril JC; Cacabelos N; Kazantsev AG; Vostrov AV; Corzo L; Cacabelos P; Goldgaber D
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
    Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
    Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomics and pharmacogenomics of dementia.
    Cacabelos R; Martínez-Bouza R
    CNS Neurosci Ther; 2011 Oct; 17(5):566-76. PubMed ID: 20718828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics and therapeutic strategies for dementia.
    Cacabelos R
    Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
    Cacabelos R
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.
    Cacabelos R; Meyyazhagan A; Carril JC; Cacabelos P; Teijido Ó
    J Pers Med; 2018 Jan; 8(1):. PubMed ID: 29301387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.
    Cacabelos R; Martínez R; Fernández-Novoa L; Carril JC; Lombardi V; Carrera I; Corzo L; Tellado I; Leszek J; McKay A; Takeda M
    Int J Alzheimers Dis; 2012; 2012():518901. PubMed ID: 22482072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic protocols in CNS disorders and dementia.
    Cacabelos R
    Neurodegener Dis; 2010; 7(1-3):167-9. PubMed ID: 20197699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
    Cacabelos R; Naidoo V; Martínez-Iglesias O; Corzo L; Cacabelos N; Pego R; Carril JC
    Methods Mol Biol; 2022; 2547():275-387. PubMed ID: 36068470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.
    Cacabelos R
    Neurodegener Dis; 2008; 5(3-4):176-8. PubMed ID: 18322383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of anxiety and depression in Alzheimer's disease.
    Cacabelos R; Carril JC; Corzo L; Pego R; Cacabelos N; Alcaraz M; Muñiz A; Martínez-Iglesias O; Naidoo V
    Pharmacogenomics; 2023 Jan; 24(1):27-57. PubMed ID: 36628952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
    Cacabelos R
    Neuropsychiatr Dis Treat; 2007 Jun; 3(3):303-33. PubMed ID: 19300564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics for the treatment of dementia.
    Cacabelos R
    Ann Med; 2002; 34(5):357-79. PubMed ID: 12452480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
    Cacabelos R
    Expert Opin Pharmacother; 2005 Oct; 6(12):1967-87. PubMed ID: 16197352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.